LOTTE BIOLOGICS Bolstered its CDMO Expansion in North America and Asia Announcement Lotte Biologics’ CEO James Park is leveraging its growth as a global Contract development and manufacturing organization (CDMO) company. This year, the company has elevated its CDMO business expansion wit...
Glioblastoma Funding Skyrockets as this Condition Raises Concern Among Nonprofits Announcement According to research, glioblastoma is a life-threatening brain cancer that is difficult to treat. The recent acquisitions by Merck and Jazz Pharmaceuticals, along with the development of innovative ...
New Disease Suspected in Ovarian Cancer Patients Announcement The overall survival (OS) rate for advanced ovarian cancer has consistently been stagnant for almost four decades, because of its steady recurring process. Though patients react safely to the initial chemotherapy and surgeries, it h...
Demetra to Launch a New Global Spine Division by Acquiring Orthofundamentals LLC Announcement Demetra, a well-established and innovative international medical company, and a leader in spacers, biomaterials, and bone cements for PJI infection control and orthopedic applications, has acquired Or...
Mabwell Received a Green Signal for CDH17 Announcement Manwell, an innovative and leading biopharmaceutical company, the pioneer of the entire industry chain, declared that its proprietary CDH17-focused antibody-drug conjugate (ADC), 7MW4911, has received an acceptance from china’s natio...
Genvira and NRC were Highlighted for their Collaborative Project Announcement Genvira Biosciences Inc., a pioneering Canadian innovator in viral vectors, LabSkin Limited, a global leader in 3D in vitro human skin models, and the National Research Council of Canada (NRC) will be introducing a c...
Silexion’s Robust Preclinical Data Dhowed Excellent Results Announcement Silexion Therapeutics Corp., a global clinical-stage biotechnology company developing RNA interference (RNAi) therapies for KRAS-targeted cancers, revealed excellent new preclinical data results, stating the inhibit...
Zenara’s Final Approval for its New Capsules Announcement Zenara Pharma Private Limited, a pioneering biophore company, finally received approval from the FDA for its abbreviated new drug application (ANDA) named Sertraline Hydrochloride Capsules (SHC), 150 mg and 200 mg. It is the first...
Azenta and Frenova’s Partnership to Advance Genomic Research in Nephrology Announcement Frenova, a division of Fresenius Nephronomics and Medical Care, a renal precision medicine company, and Azenta Inc. entered into a partnership to head start with data generation for Frenova’s tr...
According to Precedence Research, the global in-vitro inflammatory bowel disease diagnostics market size is expected to be worth around USD 3.02 billion in 2034, increasing from USD 1.84 billion in 2025. The market is poised to grow at a CAGR of 4.9% from 2025 to 2034. In-Vitro Inflammatory Bowel...
